CD8alpha mutants
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 16, 2008
Grant Date -
Aug 12, 2004
app pub date -
Jun 14, 2002
filing date -
Jun 14, 2001
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention provides modified CD8 molecules whose binding to MHC is enhanced compared to wild-type CD8, wherein Ser.sub.53 of at least one CD8.alpha. chain thereof is mutated to another amino acid. It also provides nucleic acids encoding such molecules and methods of using such molecules and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully